BCL2 and diffuse large B-cell lymphoma: In contrast, in FL and DLBCL, venetoclax monotherapy has been less successful, with reported response rates of only 38% and 18% respectively.298 Many FL and DLBCL cells express high levels of BCL2 due to either chromosomal translocation or amplification, and therefore such inherent resistance to BCL2 inhibition was unanticipated.